ProBioGen and Surface Oncology Sign Second Antibody Manufacturing Program

ProBioGen logo2

Tumor Microenvironment Antibody, Parallel Cell Line Development till GMP Manufacturing

Berlin, Germany, March 08, 2018 / B3C newswire / -- ProBioGen AG, a premier German service & technology provider for complex therapeutic glycoproteins announced signing the second antibody development project with Cambridge, MA-based Surface Oncology Inc., an immuno-oncology company developing next-generation antibody therapies that target the tumor microenvironment.

Under the terms of the agreement Surface Oncology will contract with ProBioGen to develop and manufacture another antibody for potential use in clinical trials. ProBioGen will develop several stable cell lines in parallel, gradually reduce the candidate number and conclude with process development and GMP manufacturing for a single antibody product candidate. The advantage of this approach is the meticulous analysis of several candidates at the same time while strongly reducing time lines.

ProBioGen’s CBO, Dr Gabriele Schneider commented: “We have worked together with Surface Oncology very well for quite a while and this is now our second potential clinical antibody project together. We have established a seamless team working across our companies and we are very pleased to continue to expand this relationship with Surface Oncology”.


About ProBioGen AG
ProBioGen is a premier, Berlin-based specialist for developing and manufacturing complex therapeutic glycoproteins. Combining both state-of-the-art development platforms, based on ProBioGen’s CHO.RiGHT® expression and manufacturing platform, together with intelligent product-specific technologies, yields biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and following reliable GMP manufacturing is performed by a highly skilled and experienced team.
All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen was founded 1994, is privately owned and located in Berlin, Germany.


Contact

Dr Gabriele Schneider
Chief Business Officer
ProBioGen AG
Goethestr. 54
13086 Berlin, Germany
+49 30 924 006-0
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
Ok